Mesa Laboratories (NASDAQ:MLAB) PT Lowered to $106.00

Mesa Laboratories (NASDAQ:MLAB) had its price target cut by Evercore ISI from $120.00 to $106.00 in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have an outperform rating on the medical instruments supplier’s stock.

Mesa Laboratories Price Performance

Shares of NASDAQ:MLAB opened at $87.73 on Tuesday. The firm has a 50 day moving average of $104.39 and a 200-day moving average of $102.69. The stock has a market capitalization of $472.86 million, a PE ratio of -1.86 and a beta of 0.86. The company has a current ratio of 0.37, a quick ratio of 1.86 and a debt-to-equity ratio of 0.58. Mesa Laboratories has a 12 month low of $82.86 and a 12 month high of $145.46.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings results on Wednesday, June 5th. The medical instruments supplier reported $2.25 earnings per share (EPS) for the quarter. The company had revenue of $58.90 million for the quarter. Mesa Laboratories had a negative net margin of 117.61% and a positive return on equity of 10.10%. On average, equities research analysts predict that Mesa Laboratories will post 6.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Mesa Laboratories

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD grew its holdings in Mesa Laboratories by 6.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,873 shares of the medical instruments supplier’s stock worth $316,000 after acquiring an additional 175 shares during the last quarter. EntryPoint Capital LLC grew its holdings in Mesa Laboratories by 35.2% during the 1st quarter. EntryPoint Capital LLC now owns 741 shares of the medical instruments supplier’s stock worth $81,000 after acquiring an additional 193 shares during the last quarter. Quadrant Capital Group LLC grew its holdings in Mesa Laboratories by 515.6% during the 4th quarter. Quadrant Capital Group LLC now owns 277 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 232 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in Mesa Laboratories by 4.5% during the 1st quarter. BNP Paribas Financial Markets now owns 7,565 shares of the medical instruments supplier’s stock worth $830,000 after acquiring an additional 327 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co grew its holdings in Mesa Laboratories by 7.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 6,968 shares of the medical instruments supplier’s stock worth $761,000 after acquiring an additional 494 shares during the last quarter. 90.60% of the stock is owned by institutional investors.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.